Results 81 to 90 of about 12,482 (250)
Clinical &Experimental Allergy, EarlyView.3 years follow‐up study to a DBPC dose‐finding trial investigating subcutaneous immunotherapy with T502 in birch‐pollen induced allergic rhinoconjunctivitis. 154 birch‐pollen allergic adults received short‐course treatment of 10,000 mTU/mL of T502 for 2 years and were observed during the next season without treatment.
Ralph Mösges +15 more
wiley +1 more source
COVID-19 lockdown and seasonal allergic rhinitis: our experience in 40 patients
, 2021 The aim of this article was to study the course of seasonal allergic rhinitis during COVID-19 lockdown in order to understand if being quarantined at home for a long time can constitute a protective factor for allergic ...
Fortunato, Francesca +6 more
core +1 more source
European Journal of Inflammation, 2011 It is well known that the fibrinolytic system actively participates in inflammatory processes. To investigate the role of the urokinase system in atopic allergy, we assessed circulating levels of urokinase-type plasminogen activator (uPA) and its soluble
A. Kasperska-Zajac +4 more
doaj +1 more source
Olfactory dysfunction in seasonal and perennial allergic rhinitis
Acta Oto-Laryngologica, 2012 The limitation in olfactory function in patients with seasonal allergic rhinitis (AR) can be ascribed to an increase in eosinophilic and mast cell activity in the olfactory cleft. Therefore, the decrease in olfactory functions seems to be predominantly caused by the inflammation of the epithelium and not by the obstruction of the nose caused by the ...
Becker, Sven +5 more
openaire +3 more sources
Comparison of Allergic Rhinitis Treatments on Utilities and Quality of Life: A MASK‐air Study
Clinical &Experimental Allergy, EarlyView.This mHealth study has shown that fixed combinations of intranasal antihistamines and corticosteroids were associated with higher quality of life than oral antihistamines and intranasal antihistamines. Both intranasal corticosteroids and oral antihistamines were associated with higher quality of life than intranasal antihistamines.
Nuno Lourenço‐Silva +27 more
wiley +1 more source
Intranasal Ciclesonide in Allergic Rhinitis
, 2010 Allergic rhinitis affects more than 20% and is responsible for very high direct and indirect costs. Nasal corticosteroids are the principle pharmaceutical option for the treatment of allergic rhinitis.
Harissios Vliagoftis
core +1 more source
Iranian South Medical Journal, 2014 Background: Oral allergy syndrome (OAS) characterized by oral IgE-mediated symptoms, which is caused by cross-reactivity between proteins in pollens, fresh fruit and vegetables. OAS is presents in 40% to 80% of Allergic rhinitis patients.
Farahzad Jabbari Azad +2 more
doaj
New guidelines for the treatment of seasonal allergic rhinitis
Advances in Dermatology and Allergology, 2019 The paper discusses the classification and forms of allergic rhinitis with a special focus on seasonal allergic rhinitis (SAR). The general principles of SAR management are presented, including the role of nasal glucocorticoids, nasal and oral antihistamines, and antileukotrienes.
Emeryk, Andrzej +2 more
openaire +3 more sources
, 2018 BACKGROUND Health-related social media data are increasingly used in disease-surveillance studies, which have demonstrated moderately high correlations between the number of social media posts and the number ...
Eiji Aramaki +3 more
core +1 more source